LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 41

Search options

  1. Article: Death by a Thousand Cuts â€" Combining Kinase Inhibitors for Selective Target Inhibition and Rational Polypharmacology.

    Outhwaite, Ian R / Singh, Sukrit / Berger, Benedict-Tilman / Knapp, Stefan / Chodera, John D / Seeliger, Markus A

    bioRxiv : the preprint server for biology

    2023  

    Abstract: Kinase inhibitors are successful therapeutics in the treatment of cancers and autoimmune diseases and are useful tools in biomedical research. The high sequence and structural conservation of the catalytic kinase domain complicates the development of ... ...

    Abstract Kinase inhibitors are successful therapeutics in the treatment of cancers and autoimmune diseases and are useful tools in biomedical research. The high sequence and structural conservation of the catalytic kinase domain complicates the development of specific kinase inhibitors. As a consequence, most kinase inhibitors also inhibit off-target kinases which complicates the interpretation of phenotypic responses. Additionally, inhibition of off-targets may cause toxicity in patients. Therefore, highly selective kinase inhibition is a major goal in both biomedical research and clinical practice. Currently, efforts to improve selective kinase inhibition are dominated by the development of new kinase inhibitors. Here, we present an alternative solution to this problem by combining inhibitors with divergent off-target activities. We have developed a multicompound-multitarget scoring (MMS) method framework that combines inhibitors to maximize target inhibition and to minimize off-target inhibition. Additionally, this framework enables rational polypharmacology by allowing optimization of inhibitor combinations against multiple selected on-targets and off-targets. Using MMS with previously published chemogenomic kinase inhibitor datasets we determine inhibitor combinations that achieve potent activity against a target kinase and that are more selective than the most selective single inhibitor against that target. We validate the calculated effect and selectivity of a combination of inhibitors using the
    Language English
    Publishing date 2023-01-16
    Publishing country United States
    Document type Preprint
    DOI 10.1101/2023.01.13.523972
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Death by a thousand cuts through kinase inhibitor combinations that maximize selectivity and enable rational multitargeting.

    Outhwaite, Ian R / Singh, Sukrit / Berger, Benedict-Tilman / Knapp, Stefan / Chodera, John D / Seeliger, Markus A

    eLife

    2023  Volume 12

    Abstract: Kinase inhibitors are successful therapeutics in the treatment of cancers and autoimmune diseases and are useful tools in biomedical research. However, the high sequence and structural conservation of the catalytic kinase domain complicate the ... ...

    Abstract Kinase inhibitors are successful therapeutics in the treatment of cancers and autoimmune diseases and are useful tools in biomedical research. However, the high sequence and structural conservation of the catalytic kinase domain complicate the development of selective kinase inhibitors. Inhibition of off-target kinases makes it difficult to study the mechanism of inhibitors in biological systems. Current efforts focus on the development of inhibitors with improved selectivity. Here, we present an alternative solution to this problem by combining inhibitors with divergent off-target effects. We develop a multicompound-multitarget scoring (MMS) method that combines inhibitors to maximize target inhibition and to minimize off-target inhibition. Additionally, this framework enables optimization of inhibitor combinations for multiple on-targets. Using MMS with published kinase inhibitor datasets we determine potent inhibitor combinations for target kinases with better selectivity than the most selective single inhibitor and validate the predicted effect and selectivity of inhibitor combinations using in vitro and in cellulo techniques. MMS greatly enhances selectivity in rational multitargeting applications. The MMS framework is generalizable to other non-kinase biological targets where compound selectivity is a challenge and diverse compound libraries are available.
    MeSH term(s) Humans ; Protein Kinase Inhibitors/pharmacology ; Protein Kinase Inhibitors/chemistry ; Antineoplastic Agents/therapeutic use ; Phosphotransferases ; Catalytic Domain ; Neoplasms/drug therapy
    Chemical Substances Protein Kinase Inhibitors ; Antineoplastic Agents ; Phosphotransferases (EC 2.7.-)
    Language English
    Publishing date 2023-12-04
    Publishing country England
    Document type Journal Article
    ZDB-ID 2687154-3
    ISSN 2050-084X ; 2050-084X
    ISSN (online) 2050-084X
    ISSN 2050-084X
    DOI 10.7554/eLife.86189
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article: Resistance to kinase inhibition through shortened target engagement.

    Rangwala, Aziz M / Berger, Benedict-Tilman / Robers, Matthew B / Knapp, Stefan / Seeliger, Markus A

    Molecular & cellular oncology

    2022  Volume 9, Issue 1, Page(s) 2029999

    Abstract: Imatinib, a selective inhibitor of the breakpoint cluster region (BCR)-ABL kinase, is the poster child for targeted cancer therapeutics. However, its efficacy is limited by resistance mutations. Using a quantitative bioluminescence resonance energy ... ...

    Abstract Imatinib, a selective inhibitor of the breakpoint cluster region (BCR)-ABL kinase, is the poster child for targeted cancer therapeutics. However, its efficacy is limited by resistance mutations. Using a quantitative bioluminescence resonance energy transfer assay in living cells, we identified ABL kinase mutations that could cause imatinib resistance by altering drug residence time.
    Language English
    Publishing date 2022-01-22
    Publishing country United States
    Document type Journal Article
    ISSN 2372-3556
    ISSN 2372-3556
    DOI 10.1080/23723556.2022.2029999
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article: Design and Synthesis of Pyrazole-Based Macrocyclic Kinase Inhibitors Targeting BMPR2.

    Amrhein, Jennifer A / Wang, Guiqun / Berger, Benedict-Tilman / Berger, Lena M / Kalampaliki, Amalia D / Krämer, Andreas / Knapp, Stefan / Hanke, Thomas

    ACS medicinal chemistry letters

    2023  Volume 14, Issue 6, Page(s) 833–840

    Abstract: Bone morphogenetic protein (BMP) signaling is mediated by transmembrane protein kinases that form heterotetramers consisting of type-I and type-II receptors. Upon BMP binding, the constitutively active type-II receptors activate specific type-I receptors ...

    Abstract Bone morphogenetic protein (BMP) signaling is mediated by transmembrane protein kinases that form heterotetramers consisting of type-I and type-II receptors. Upon BMP binding, the constitutively active type-II receptors activate specific type-I receptors by transphosphorylation, resulting in the phosphorylation of SMAD effector proteins. Drug discovery in the receptor tyrosine kinase-like (TKL) family has largely focused on type-I receptors, with few inhibitors that have been published targeting type-II receptors. BMPR2 is involved in several diseases, most notably pulmonary arterial hypertension, but also contributes to Alzheimer's disease and cancer. Here, we report that macrocyclization of the promiscuous inhibitor
    Language English
    Publishing date 2023-05-30
    Publishing country United States
    Document type Journal Article
    ISSN 1948-5875
    ISSN 1948-5875
    DOI 10.1021/acsmedchemlett.3c00127
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Development of Potent Dual BET/HDAC Inhibitors via Pharmacophore Merging and Structure-Guided Optimization.

    Bauer, Nicolas / Balourdas, Dimitrios-Ilias / Schneider, Joel R / Zhang, Xin / Berger, Lena M / Berger, Benedict-Tilman / Schwalm, Martin P / Klopp, Nick A / Siveke, Jens T / Knapp, Stefan / Joerger, Andreas C

    ACS chemical biology

    2024  Volume 19, Issue 2, Page(s) 266–279

    Abstract: Bromodomain and extra-terminal domain (BET) proteins and histone deacetylases (HDACs) are prime targets in cancer therapy. Recent research has particularly focused on the development of dual BET/HDAC inhibitors for hard-to-treat tumors, such as ... ...

    Abstract Bromodomain and extra-terminal domain (BET) proteins and histone deacetylases (HDACs) are prime targets in cancer therapy. Recent research has particularly focused on the development of dual BET/HDAC inhibitors for hard-to-treat tumors, such as pancreatic cancer. Here, we developed a new series of potent dual BET/HDAC inhibitors by choosing starting scaffolds that enabled us to optimally merge the two functionalities into a single compound. Systematic structure-guided modification of both warheads then led to optimized binders that were superior in potency to both parent compounds, with the best molecules of this series binding to both BRD4 bromodomains as well as HDAC1/2 with EC
    MeSH term(s) Humans ; Histone Deacetylase Inhibitors/pharmacology ; Histone Deacetylase Inhibitors/chemistry ; Nuclear Proteins/metabolism ; Transcription Factors/metabolism ; Pharmacophore ; Pancreatic Neoplasms/drug therapy ; Carcinoma ; Cell Line, Tumor ; Antineoplastic Agents/pharmacology ; Antineoplastic Agents/chemistry ; RNA-Binding Proteins ; Bromodomain Containing Proteins ; Cell Cycle Proteins/metabolism
    Chemical Substances Histone Deacetylase Inhibitors ; Nuclear Proteins ; Transcription Factors ; Antineoplastic Agents ; HEXIM1 protein, human ; RNA-Binding Proteins ; BRD4 protein, human ; Bromodomain Containing Proteins ; Cell Cycle Proteins
    Language English
    Publishing date 2024-01-31
    Publishing country United States
    Document type Journal Article
    ISSN 1554-8937
    ISSN (online) 1554-8937
    DOI 10.1021/acschembio.3c00427
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article: Back-pocket optimization of 2-aminopyrimidine-based macrocycles leads to potent dual EPHA2/GAK kinase inhibitors with antiviral activity.

    Gerninghaus, Joshua / Zhubi, Rezart / Krämer, Andreas / Karim, Marwah / Tran, Do Hoang Nhu / Joerger, Andreas C / Schreiber, Christian / Berger, Lena M / Berger, Benedict-Tilman / Ehret, Theresa A L / Elson, Lewis / Lenz, Christopher / Saxena, Krishna / Müller, Susanne / Einav, Shirit / Knapp, Stefan / Hanke, Thomas

    bioRxiv : the preprint server for biology

    2024  

    Abstract: Macrocyclization of acyclic compounds is a powerful strategy for improving inhibitor potency and selectivity. Here, we developed a 2-aminopyrimidine-based macrocyclic dual EPHA2/GAK kinase inhibitor as a chemical tool to study the role of these two ... ...

    Abstract Macrocyclization of acyclic compounds is a powerful strategy for improving inhibitor potency and selectivity. Here, we developed a 2-aminopyrimidine-based macrocyclic dual EPHA2/GAK kinase inhibitor as a chemical tool to study the role of these two kinases in viral entry and assembly. Starting with a promiscuous macrocyclic inhibitor,
    Language English
    Publishing date 2024-02-18
    Publishing country United States
    Document type Preprint
    DOI 10.1101/2024.02.18.580805
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Development of Selective Pyrido[2,3-

    Rak, Marcel / Menge, Amelie / Tesch, Roberta / Berger, Lena M / Balourdas, Dimitrios-Ilias / Shevchenko, Ekaterina / Krämer, Andreas / Elson, Lewis / Berger, Benedict-Tilman / Abdi, Ismahan / Wahl, Laurenz M / Poso, Antti / Kaiser, Astrid / Hanke, Thomas / Kronenberger, Thales / Joerger, Andreas C / Müller, Susanne / Knapp, Stefan

    Journal of medicinal chemistry

    2024  Volume 67, Issue 5, Page(s) 3813–3842

    Abstract: Mammalian STE20-like (MST) kinases 1-4 play key roles in regulating the Hippo and autophagy pathways, and their dysregulation has been implicated in cancer development. In contrast to the well-studied MST1/2, the roles of MST3/4 are less clear, in part ... ...

    Abstract Mammalian STE20-like (MST) kinases 1-4 play key roles in regulating the Hippo and autophagy pathways, and their dysregulation has been implicated in cancer development. In contrast to the well-studied MST1/2, the roles of MST3/4 are less clear, in part due to the lack of potent and selective inhibitors. Here, we re-evaluated literature compounds, and used structure-guided design to optimize the p21-activated kinase (PAK) inhibitor G-5555 (
    MeSH term(s) Animals ; Protein Serine-Threonine Kinases/metabolism ; p21-Activated Kinases ; Mammals/metabolism
    Chemical Substances Protein Serine-Threonine Kinases (EC 2.7.11.1) ; p21-Activated Kinases (EC 2.7.11.1)
    Language English
    Publishing date 2024-02-29
    Publishing country United States
    Document type Journal Article
    ZDB-ID 218133-2
    ISSN 1520-4804 ; 0022-2623
    ISSN (online) 1520-4804
    ISSN 0022-2623
    DOI 10.1021/acs.jmedchem.3c02217
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: Deep Annotation of Donated Chemical Probes (DCP) in Organotypic Human Liver Cultures and Patient-Derived Organoids from Tumor and Normal Colorectum.

    Tredup, Claudia / Ndreshkjana, Benardina / Schneider, Natalie S / Tjaden, Amelie / Kemas, Aurino M / Youhanna, Sonia / Lauschke, Volker M / Berger, Benedict-Tilman / Krämer, Andreas / Berger, Lena M / Röhm, Sandra / Knapp, Stefan / Farin, Henner F / Müller, Susanne

    ACS chemical biology

    2023  Volume 18, Issue 4, Page(s) 822–836

    Abstract: Well-characterized small molecules are essential tools for studying the biology and therapeutic relevance of a target protein. However, many compounds reported in the literature and routinely studied in biomedical research lack the potency and ... ...

    Abstract Well-characterized small molecules are essential tools for studying the biology and therapeutic relevance of a target protein. However, many compounds reported in the literature and routinely studied in biomedical research lack the potency and selectivity required for mechanistic cellular studies on the function of a given protein. Furthermore, commercially available compounds often do not include useful tools developed by industry as part of their research and development efforts, as they frequently remain proprietary. The freely available donated chemical probe (DCP) library, fueled by generous donations of compounds from industry and academia, enables easy access to a steadily growing collection of these valuable and well-characterized tools. Here, we provide a systematic description of the current DCP library collection and their associated comprehensive characterization data, including a variety of
    MeSH term(s) Humans ; Liver ; Microphysiological Systems ; Neoplasms/metabolism ; Organoids/metabolism ; Organoids/pathology ; Proteins/metabolism ; Small Molecule Libraries/classification ; Molecular Probes/chemistry ; Molecular Probes/pharmacology
    Chemical Substances Proteins ; Small Molecule Libraries ; Molecular Probes
    Language English
    Publishing date 2023-03-21
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ISSN 1554-8937
    ISSN (online) 1554-8937
    DOI 10.1021/acschembio.2c00877
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: Discovery of Potent and Exquisitely Selective Inhibitors of Kinase CK1 with Tunable Isoform Selectivity.

    Němec, Václav / Khirsariya, Prashant / Janovská, Pavlína / Moyano, Paula Martín / Maier, Lukáš / Procházková, Petra / Kebková, Pavlína / Gybel', Tomáš / Berger, Benedict-Tilman / Chaikuad, Apirat / Reinecke, Maria / Kuster, Bernhard / Knapp, Stefan / Bryja, Vítězslav / Paruch, Kamil

    Angewandte Chemie (International ed. in English)

    2023  Volume 62, Issue 11, Page(s) e202217532

    Abstract: Casein kinases 1 (CK1) are key signaling molecules that have emerged recently as attractive therapeutic targets in particular for the treatment of hematological malignancies. Herein, we report the identification of a new class of potent and highly ... ...

    Abstract Casein kinases 1 (CK1) are key signaling molecules that have emerged recently as attractive therapeutic targets in particular for the treatment of hematological malignancies. Herein, we report the identification of a new class of potent and highly selective inhibitors of CK1α, δ and ϵ. Based on their optimal in vitro and in vivo profiles and their exclusive selectivity, MU1250, MU1500 and MU1742 were selected as quality chemical probes for those CK1 isoforms. At proper concentrations, MU1250 and MU1500 allow for specific targeting of CK1δ or dual inhibition of CK1δ/ϵ in cells. The compound MU1742 also efficiently inhibits CK1α and, to our knowledge, represents the first potent and highly selective inhibitor of this enzyme. In addition, we demonstrate that the central 1H-pyrrolo[2,3-b]pyridine-imidazole pharmacophore can be used as the basis of highly selective inhibitors of other therapeutically relevant protein kinases, e.g. p38α, as exemplified by the compound MU1299.
    MeSH term(s) Casein Kinase I/metabolism ; Protein Isoforms/metabolism ; Protein Kinase Inhibitors/chemistry ; Signal Transduction ; Humans
    Chemical Substances Casein Kinase I (EC 2.7.11.1) ; Protein Isoforms ; Protein Kinase Inhibitors
    Language English
    Publishing date 2023-02-02
    Publishing country Germany
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 2011836-3
    ISSN 1521-3773 ; 1433-7851
    ISSN (online) 1521-3773
    ISSN 1433-7851
    DOI 10.1002/anie.202217532
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: Synthesis of Pyrazole-Based Macrocycles Leads to a Highly Selective Inhibitor for MST3.

    Amrhein, Jennifer Alisa / Berger, Lena Marie / Balourdas, Dimitrios-Ilias / Joerger, Andreas C / Menge, Amelie / Krämer, Andreas / Frischkorn, Julia Marie / Berger, Benedict-Tilman / Elson, Lewis / Kaiser, Astrid / Schubert-Zsilavecz, Manfred / Müller, Susanne / Knapp, Stefan / Hanke, Thomas

    Journal of medicinal chemistry

    2023  Volume 67, Issue 1, Page(s) 674–690

    Abstract: MST1, MST2, MST3, MST4, and YSK1 are conserved members of the mammalian sterile 20-like serine/threonine (MST) family that regulate cellular functions such as proliferation and migration. The MST3 isozyme plays a role in regulating cell growth and ... ...

    Abstract MST1, MST2, MST3, MST4, and YSK1 are conserved members of the mammalian sterile 20-like serine/threonine (MST) family that regulate cellular functions such as proliferation and migration. The MST3 isozyme plays a role in regulating cell growth and apoptosis, and its dysregulation has been linked to high-grade tumors. To date, there are no isoform-selective inhibitors that could be used for validating the role of MST3 in tumorigenesis. We designed a series of 3-aminopyrazole-based macrocycles based on the structure of a promiscuous inhibitor. By varying the moieties targeting the solvent-exposed region and optimizing the linker, macrocycle JA310 (
    MeSH term(s) Animals ; Protein Serine-Threonine Kinases/metabolism ; Phosphorylation ; Apoptosis ; Mammals/metabolism
    Chemical Substances Protein Serine-Threonine Kinases (EC 2.7.11.1)
    Language English
    Publishing date 2023-12-21
    Publishing country United States
    Document type Journal Article
    ZDB-ID 218133-2
    ISSN 1520-4804 ; 0022-2623
    ISSN (online) 1520-4804
    ISSN 0022-2623
    DOI 10.1021/acs.jmedchem.3c01980
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top